PURPOSE: SOX9 is an important transcription factor required for development and has been implicated in several types of cancer. However, SOX9 has never been linked to lung cancer to date. Here, we show that SOX9 expression is upregulated in lung adenocarcinoma and show how it is associated with cancer cell growth. EXPERIMENTAL DESIGN: Data mining with five microarray data sets containing 490 clinical samples, quantitative reverse transcription-PCR validation assay in 57 independent samples, and immunohistochemistry assay with tissue microarrays containing 170 lung tissue cores were used to profile SOX9 mRNA and protein expression. Short interference RNA suppression of SOX9 in cell lines was used to scrutinize functional role(s) of SOX9 and associated molecular mechanisms. RESULTS: SOX9 mRNA and protein were consistently overexpressed in the majority of lung adenocarcinoma. Knockdown of SOX9 in lung adenocarcinoma cell lines resulted in marked decrease of adhesive and anchorage-independent growth in concordance with the upregulation of p21 (CDKN1A) and downregulation of CDK4. In agreement with higher SOX9 expression level in lung adenocarcinoma, the p21 mRNA level was significantly lower in tumors than that in normal tissues, whereas the opposite was true for CDK4, supporting the notion that SOX9 negatively and positively regulated p21 and CDK4, respectively. Finally, whereas SOX9-knockdown cells showed significantly attenuated tumorigenicity in mice, SOX9 transfectants consistently showed markedly stronger tumorigenicity. CONCLUSIONS: Our data suggest that SOX9 is a new hallmark of lung adenocarcinoma, in which SOX9 might contribute to gain of tumor growth potential, possibly acting through affecting the expression of cell cycle regulators p21 and CDK4.
PURPOSE:SOX9 is an important transcription factor required for development and has been implicated in several types of cancer. However, SOX9 has never been linked to lung cancer to date. Here, we show that SOX9 expression is upregulated in lung adenocarcinoma and show how it is associated with cancer cell growth. EXPERIMENTAL DESIGN: Data mining with five microarray data sets containing 490 clinical samples, quantitative reverse transcription-PCR validation assay in 57 independent samples, and immunohistochemistry assay with tissue microarrays containing 170 lung tissue cores were used to profile SOX9 mRNA and protein expression. Short interference RNA suppression of SOX9 in cell lines was used to scrutinize functional role(s) of SOX9 and associated molecular mechanisms. RESULTS:SOX9 mRNA and protein were consistently overexpressed in the majority of lung adenocarcinoma. Knockdown of SOX9 in lung adenocarcinoma cell lines resulted in marked decrease of adhesive and anchorage-independent growth in concordance with the upregulation of p21 (CDKN1A) and downregulation of CDK4. In agreement with higher SOX9 expression level in lung adenocarcinoma, the p21 mRNA level was significantly lower in tumors than that in normal tissues, whereas the opposite was true for CDK4, supporting the notion that SOX9 negatively and positively regulated p21 and CDK4, respectively. Finally, whereas SOX9-knockdown cells showed significantly attenuated tumorigenicity in mice, SOX9 transfectants consistently showed markedly stronger tumorigenicity. CONCLUSIONS: Our data suggest that SOX9 is a new hallmark of lung adenocarcinoma, in which SOX9 might contribute to gain of tumor growth potential, possibly acting through affecting the expression of cell cycle regulators p21 and CDK4.
Authors: Ciric To; Carol S Ringelberg; Darlene B Royce; Charlotte R Williams; Renee Risingsong; Michael B Sporn; Karen T Liby Journal: Carcinogenesis Date: 2015-05-04 Impact factor: 4.944
Authors: Shumei Song; Jaffer A Ajani; Soichiro Honjo; Dipen M Maru; Qiongrong Chen; Ailing W Scott; Todd R Heallen; Lianchun Xiao; Wayne L Hofstetter; Brian Weston; Jeffrey H Lee; Roopma Wadhwa; Kazuki Sudo; John R Stroehlein; James F Martin; Mien-Chie Hung; Randy L Johnson Journal: Cancer Res Date: 2014-06-06 Impact factor: 12.701
Authors: Antonella F M Dost; Aaron L Moye; Marall Vedaie; Linh M Tran; Eileen Fung; Dar Heinze; Carlos Villacorta-Martin; Jessie Huang; Ryan Hekman; Julian H Kwan; Benjamin C Blum; Sharon M Louie; Samuel P Rowbotham; Julio Sainz de Aja; Mary E Piper; Preetida J Bhetariya; Roderick T Bronson; Andrew Emili; Gustavo Mostoslavsky; Gregory A Fishbein; William D Wallace; Kostyantyn Krysan; Steven M Dubinett; Jane Yanagawa; Darrell N Kotton; Carla F Kim Journal: Cell Stem Cell Date: 2020-09-04 Impact factor: 24.633